About Aescap
Aescap is a venture capital firm founded in 2005. It is primarily based out of Amsterdam, Netherlands. As of Mar 2017, Aescap has invested in 12 companies. It primarily invests in Series A round in Belgium based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series B round of Orphazyme ApS Overall, Aescap portfolio has seen 3 IPOs and 3 acquisitions including key companies like Biocartis, Orphazyme ApS and Avantium. A lot of funds co-invest with Aescap, with names like TVM Capital sharing a substantial percentage of its portfolio. Aescap has team of 8 people including 1 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 1 more
Portfolio IPOs
Aescap's List of Top Investments
Aescap has a portfolio of 12 companies. Their most notable investments are in i-Optics and i-Optics.Their portfolio spans across Belgium, Netherlands, United Kingdom and 6 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 2 other sectors, across stages such as Series A, Series B and 1 more. Here is the list of top investments by Aescap:
1. Biocartis
Manufacturer of automated molecular diagnostic systems for oncology biomarker testing. These systems perform molecular analysis on tissue samples to detect genetic mutations and gene fusions. The technology supports clinical decision-making by providing results for various cancer types. The hardware and associated assays facilitate the identification of biomarkers required for treatment selection.
Key facts about Biocartis
- Founded Year: 2007
- Location: Mechelen (Belgium)
- Annual Revenue: €10M - €50M as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $305M
- Employee Count: 314 as on Sep 30, 2026
- Investors: Advent Life Sciences, Philips and 18 Others
- Latest Funding Round: Post IPO, Sep 01, 2022, $*****
- Highlight: Public
Developer of therapeutics for the treatment of rare and genetic diseases. It develops innovative new therapies for the treatment of a family of serious genetic disorders called lysosomal storage diseases. The company has developed arimoclomol in four indications Niemann-Pick disease Type C (NPC), Gaucher disease, Amyotrophic Lateral Sclerosis (ALS), and sporadic Inclusion Body Myositis (sIBM).
Key facts about Orphazyme ApS
- Founded Year: 2009
- Location: Copenhagen (Denmark)
- Stage: Public
- Total Funding till date: $59M
- Employee Count: 141 as on Dec 31, 2021
- Investors: Kreos Capital, Life Sciences Partners and 9 Others
- Latest Funding Round: Post IPO, Sep 04, 2020, $*****
- Highlight: Public
3. Avantium
Manufacturer of renewable plant-based chemicals and circular polymer plastic materials. The organization develops and commercializes technologies that transform renewable feedstocks into high-value chemical products and polymers. By focusing on the conversion of plant-derived ingredients, the business creates alternatives to traditional petroleum-based plastics for use in packaging, textiles, and film applications. Research and development activities support the creation of chemical processes and sustainable material solutions designed for the transition to a circular economy. Operations include the licensing of proprietary technologies and the production of plant-based polymers to reduce reliance on fossil resources in the chemical industry.
Key facts about Avantium
- Founded Year: 2000
- Stage: Public
- Total Funding till date: $132M
- Employee Count: 290 as on Sep 30, 2026
- Investors: Draper Esprit, The Coca-Cola and 26 Others
- Latest Funding Round: Grant (prize money), May 26, 2025, $*****
- Highlight: Public
4. F-star
Developer of bispecific antibodies to improve the treatment of cancer. The company is developing antibody products to improve the treatment of serious diseases, with a focus on immuno-oncology and inflammation. The company's modular antibody technology allows for rapid discovery and develops bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company's lead program is FS118, that targets immune checkpoints (LAG-3) and PD-1 for the treatment of head and neck cancer.
Key facts about F-star
- Founded Year: 2006
- Location: Cambridge (United Kingdom)
- Annual Revenue: £1M - £10M as on Dec 31, 2025
- Stage: Acquired
- Total Funding till date: $23.5M
- Employee Count: 9 as on Sep 30, 2026
- Investors: Atlas Venture, Ridgeback Capital Management and 9 Others
- Latest Funding Round: Series B, Apr 13, 2011, $*****
- Highlight: Acquired
5. ActoGeniX
ActoGeniX is focused on the development and commercialization of ActoBiotics™, a novel class of orally available biopharmaceuticals for the targeted treatment of severe diseases. Its proprietary TopAct platform developed enables the molecular engineering of food-grade microbes (lactococcus lactis) to generate biologically-contained ActoBiotics™ for in situ expression and secretion of novel biotherapeutic proteins and peptides including cytokines, enzymes, hormones, and monoclonal antibodies to the oral and gastrointestinal tract. Its clinical stage products include AG013 which delivers a therapeutic peptide for the prevention and attenuation of oral mucositis, and AG014 which secretes anti-TNF-alpha Fab to treat inflammatory bowel disease with localized delivery minimizing systemic exposure. Acobiotics has the potential to facilitate targeted therapies against oral, gastrointestinal, metabolic, allergic and autoimmune diseases. The company has been acquired by Intrexon Corp. on Feb 2015.
Key facts about ActoGeniX
- Founded Year: 2006
- Location: Ghent (Belgium)
- Stage: Acquired
- Total Funding till date: $57.2M
- Employee Count: 5 as on Sep 30, 2026
- Investors: Life Sciences Partners, EQT and 8 Others
- Latest Funding Round: Series B, Apr 18, 2013, $*****
- Highlight: Acquired
Aescap's Investments by Stage
Aescap has made 6 investments in Series A stage with an average round size of $18.7M, 3 investments in Series B stage with an average round size of $17.5M and 2 investments in Series C stage with an average round size of $10.4M.Stage of entry | No. of Investments |
|---|---|
Series A | 6 |
Series B | 3 |
Series C | 2 |
Note: We have considered here, only first round of investments
Aescap's Investments by Sector
Aescap has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Energy, Energy Tech and Enterprise Applications. Notably, it has invested in 11 Tech companies, 7 Enterprise (B2B) companies, 3 Software companies and 2 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Life Sciences | 10 |
High Tech | 2 |
Energy | 1 |
Energy Tech | 1 |
Enterprise Applications | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Aescap's Investments by Geography
Aescap has made most investments in Belgium (2), followed by United Kingdom where it has made 2 investments.Country | No. of Investments |
|---|---|
Belgium | 2 |
United Kingdom | 2 |
Austria | 1 |
Denmark | 1 |
Germany | 1 |
Others | 4 |
Note: We have considered here, only first round of investments
Aescap's recent investments
Aescap has not made any investment in 2026 so far.Here are the most recent investments by Aescap:
Date | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Mar 08, 2017 | Denmark | Series B | 3464 | ||
May 22, 2015 | Netherlands | Series E | 1441 | [+3] | |
Jan 09, 2015 | Denmark | Series B | 5408 | [+3] | |
Jun 05, 2014 | - | Series D | 5077 | [+8] | |
Apr 18, 2013 | Belgium | Series B | 6572 |
IPOs and Publicly Listed companies in Aescap's Portfolio
3 of Aescap's portfolio companies have become public. Orphazyme ApS got listed on the Nordic and Baltic regions (NASDAQ OMX), in Nov 2017 at marketcap of $394M and Avantium got listed on the Euronext Exchange (Euronext) at marketcap of $295M.Here are Aescap's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Nov 16, 2017 | Sep 07, 2011 | Series A | 5096 | |
Mar 15, 2017 | Oct 29, 2008 | Series B | 8169 | |
Apr 27, 2015 | Oct 15, 2009 | Series A | 3739 |
Acquired companies in Aescap's Portfolio
3 companies from Aescap's portfolio have been acquired. The most recent acquisition was F-star in Jun 2022 by invoX Pharma for $*****.Here are Aescap's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 23, 2022 | Apr 13, 2011 | Series B | 8605 | |
Feb 13, 2015 | Feb 06, 2007 | Series A | 6851 | |
Nov 19, 2013 | Jul 30, 2009 | Series A | 8600 |
Team profile of Aescap
Aescap has a team of 8 members located in Netherlands. Aescap's team does not sit on the board of any company as of now.Co-investors of Aescap
Over the past 20 years, 84 investors have co-invested in Aescap's portfolio companies. This includes funds and angels.
- Invested before Aescap: Sunstone, Novo Holdings and 9 others have invested in rounds before Aescap. There is 1 company where Sunstone has invested before Aescap and 1 company where Novo Holdings has invested before Aescap.
- Top Co-investors of Aescap: 26 investors entered a company along with Aescap. These include investors like TVM Capital (2 companies).
- Invested after Aescap: A total of 47 investors have invested in Aescap's portfolio after their investments. Top Investors include PMV (2 companies), SFPI (2 companies) and Europa (2 companies).
Recent News related to Aescap
•
Orphazyme hauls in $24M to advance its rare disease contender | FierceBiotechFierce Biotech•Jan 09, 2015•Orphazyme ApS, Aescap, Sunstone, Idinvest Partners and 2 others
•
Retinal imaging startup i-Optics raises further milionsStartupJuncture•Apr 02, 2013•i-Optics, Aescap, HBM Partners, NIBC and 1 other
•
Orphazyme lands $20M A round to back new drugs for rare genetic disorder | FierceBiotechFierce Biotech•Sep 07, 2011•Orphazyme ApS, Aescap, Sunstone, Novo Holdings
•
i-Optics closes 4.2 Million Euro financing roundi-Optics•Oct 28, 2010•i-Optics, Aescap, De Hoge Dennen Capital
•
Affectis Pharmaceuticals Raises €3.3M in Financing and Names Alex Martin Chief Executive Officerakampion•Mar 22, 2010•Affectis, Life Sciences Partners, Aescap, Kfw-Mittelstandbank and 2 others
•
ActoGeniX completes equity financing round of EUR 13.5 | FierceBiotechFierce Biotech•Feb 11, 2009•ActoGeniX, Gimv, Baekeland Funds, VIB and 3 others
•
Orphazyme Raises 14 Million Euro in a Series A Financing roundOrphazyme ApS•Orphazyme ApS, Aescap, Sunstone, Novo Holdings
•
ActoGeniX Series B to Move IBD Program to IND Stage | BioWorldBioWorld•ActoGeniX, Saffelberg Investments, Gimv, Baekeland Funds and 3 others
•
Shell Spinoff Avantium Raises $43.9 Million To Develop Green Plastics, Chemicals And Fuel – TechCrunchTechCrunch+•Avantium, Government of the Netherlands, Aster, Aescap and 5 others
•